August 13th 2020
The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.
August 11th 2020
Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.
August 7th 2020
Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.
August 5th 2020
Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.
July 31st 2020
Nilanjan Ghosh, MD, PhD, discusses the utility of lisocabtagene maraleucel in relapsed/refractory non-Hodgkin lymphoma.
July 24th 2020
Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.
July 23rd 2020
Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.
Single-agent selinexor was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy.
July 22nd 2020
The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.
July 21st 2020
Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.
